Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (DE:2LB)
FRANKFURT:2LB
Holding DE:2LB?
Track your performance easily
2LB Analyst Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
2LB Stock 12 Month Forecast
Average Price Target
€20.91
▲(253.22% Upside)
| Highest Price Target€30.71 | Average Price Target€20.91 | Lowest Price Target€7.20 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
01/31/25
Truist Financial
Assigned
01/30/25
Stifel Nicolaus
Reiterated
01/27/25
Wells Fargo
Assigned
01/15/25
Barclays
Assigned
01/15/25
Goldman Sachs
Reiterated
01/14/25
TD Cowen
Reiterated
11/14/24
JMP Securities
Reiterated
11/11/24
H.C. Wainwright
Reiterated
11/08/24
Mizuho Securities
Reiterated
11/08/24
UBS
€16.31
Buy
175.57%
Upside
Initiated
10/24/24
Iovance Biotherapeutics initiated with a Buy at UBSIovance Biotherapeutics initiated with a Buy at UBS
Robert W. Baird
€23.03
Buy
289.04%
Upside
Assigned
09/11/24
Baird reiterates Outperform Rating on Iovanace Biotherapeutics (IOVA)Baird analyst Colleen Kusy reiterated an Outperform rating and $24.00 price target on Iovanace Biotherapeutics (NASDAQ: IOVA).
Chardan Capital
€32.63
Buy
451.14%
Upside
Reiterated
02/19/24
Iovance Biotherapeutics' Amtagvi: A Strong Buy on Revolutionary T Cell Therapy's Approval and Market Prospects
Jefferies
€19.19→€23.03
Buy
289.04%
Upside
Reiterated
02/19/24
Iovanace Biotherapeutics (IOVA) PT Raised to $24 at JefferiesJefferies analyst Michael Yee raised the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $24.00 (from $20.00) while maintaining a Buy rating.
Best Analysts Covering Iovance Biotherapeutics
Which Analyst Should I Follow If I Want to Buy DE:2LB and Sell After:
1 Month
xxx
Success Rate
7/15 ratings generated profit
Average Return
-3.37%
assigned a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of -3.37% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+2.62%
assigned a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.62% per trade.
1 Year
Success Rate
15/32 ratings generated profit
Average Return
+17.98%
reiterated a buy rating 12 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +17.98% per trade.
2 Years
xxx
Success Rate
9/32 ratings generated profit
Average Return
-9.35%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 28.13% of your transactions generating a profit, with an average return of -9.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
2LB Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Jan 25
Strong Buy
15
9
9
8
11
Buy
3
3
3
4
6
Hold
1
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
13
14
13
18
Each month's total comprises the sum of three months' worth of ratings.
2LB Financial Forecast
2LB Stock Forecast FAQ
What is DE:2LB’s average 12-month price target, according to analysts?
Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is €20.91.
What is DE:2LB’s upside potential, based on the analysts’ average price target?
Iovance Biotherapeutics Inc has 253.22% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Iovance Biotherapeutics Inc a Buy, Sell or Hold?
Iovance Biotherapeutics Inc has a consensus rating of Strong Buy, which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is Iovance Biotherapeutics Inc’s share price target?
The average share price target for Iovance Biotherapeutics Inc is €20.91. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €30.71 ,and the lowest forecast is €7.20. The average share price target represents 253.22% Increase from the current price of €5.92.
The highest analyst share price target is €30.71 ,and the lowest forecast is €7.20. The average share price target represents 253.22% Increase from the current price of €5.92.
What do analysts say about Iovance Biotherapeutics Inc?
Iovance Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of Iovance Biotherapeutics Inc?
To buy shares of DE:2LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.